STAT highlights changes in leadership within the biotech industry, including Lance Berman's new role as chief medical officer at Basking Biosciences.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also known for his morning newsletter, Pharmalittle, and afternoon newsletter, Pharmalot. If you have news about new hires or promotions within your organization, don't hesitate to share it with us. We'll make sure to spread the word.
This week, we're highlighting Lance Berman's new role as chief medical officer at Basking Biosciences. Previously, he held a similar position at Pulmocide. While hard work is important, it's also crucial not to neglect playtime - especially for a chief medical officer. STAT+ Exclusive Story
Berman's appointment comes after a busy week of industry news. At the FDA, Makary resigned as commissioner, and Takeda announced layoffs. Meanwhile, positive results were reported for a Duchenne drug trial, and a Lilly weight loss drug study is underway.
As we continue to cover developments in biotechnology and pharmaceuticals, STAT+ offers exclusive insights and analysis that you won't find elsewhere. To access more content like this, consider subscribing to our platform today. Advertisement
For those interested in staying updated on the latest from STAT+, here are a few recent articles:
STAT Plus: U.S. Pressuring Germany on Drug Prices, FDA Upheaval, Biotech Clinical Trials
STAT Plus: CDC Plans to Transfer Monkeys to Nonprofit Sanctuary
STAT Plus: FDA's Makary Resigns, Lilly Weight Loss Drug Trial, and More
Subscribing to STAT+ provides access to in-depth analysis, newsletters, premium events, and exclusive news alerts. With various subscription plans available, there’s something for everyone.
To read more stories from STAT+, consider subscribing now.
